ALUMIS INC. 8-K

What Happened

• On January 6, 2026, Alumis Inc. filed a Current Report on Form 8-K to announce a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next‑Generation Oral Plaque Psoriasis Therapies in Phase 3 Program” and posted an updated corporate presentation to its investor website. Both documents were filed as exhibits to the 8‑K.
• The materials highlight Phase 3 program results for envudeucitinib in moderate‑to‑severe plaque psoriasis and reference company plans, including a stated aim to submit a New Drug Application (NDA) in the second half of 2026 (forward‑looking).

Key Details

• Filing date: January 6, 2026 (Form 8‑K, Other Events).
• Press release and investor presentation were filed as Exhibits 99.1 and 99.2, respectively.
• Company states an aim to submit an NDA for envudeucitinib in H2 2026 (forward‑looking statement).
• The presentation and release reference Phase 3 program performance and LUMUS Phase 2b topline timing (no new financial results or regulatory approvals reported in this 8‑K).

Why It Matters

• For investors, the release signals progress in Alumis’s lead clinical program: favorable Phase 3 messaging and an NDA timing goal (H2 2026) can be material to the company’s development timeline and valuation.
• The filing contains forward‑looking statements and explicitly warns these are subject to regulatory, clinical trial, funding and other risks; it does not constitute regulatory acceptance or approval.
• This 8‑K provides corporate and clinical updates but does not report financial results, management changes, or confirm regulatory filings have been accepted.